Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT-015 in healthy volunteers
NCT04887038Phase 1Completed
- Sponsor
- Syneos Health
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SRT-015 in Nonalcoholic steatohepatitis (NASH) (6 arms), sponsored by Syneos Health. Primary endpoints: Safety and tolerability following single and multiple oral doses up to 2 weeks, Area under the concentration-time curve from time zero to the last measurable concentration up to 2 weeks and 1 more. Started May 2021; status: completed.
02
Drugs
SRT-015
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04887038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887038.